Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use COSENTYX safely and effectively. See full prescribing information for COSENTYX. COSENTYX® (secukinumab) injection, for subcutaneous or intravenous useInitial U.S. Approval: 2015
Medication labelWhy this: Advisory · dailymed-prescription
COSENTYX® is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults and pediatric patients 6 years and older who are candidates for systemic therapy or phototherapy. COSENTYX is indicated for the treatment of active psoriatic arthritis (PsA) in adults and pediatric patients 2 years of age and older. COSENTYX is indicated for the treatment of active ankylosing spondylitis (AS) in adults and pediatric patients 12 years of age and older. COSENTYX is indicated for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in adult patients with objective signs of inflammation. COSENTYX is indicated for the treatment of active enthesitis-related arthritis (ERA) in pediatric patients 4 years of age and older. COSENTYX is indicated for the treatment of moderate to severe hidradenitis suppurativa (HS) in adults and pediatric patients 12 years of age and older.
- generic_name
- secukinumab
- product_names
- secukinumab
- ndc
- 0078-0639, 0078-0639-41, 0078-0639-68, 0078-0639-98, 0078-0639-97, 0078-1056, 0078-1056-97, 0078-1056-99, 0078-1070, 0078-1070-68, 0078-1070-96, 0078-1168, 0078-1168-61
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en